A SECOND LOOK AT PHARMACEUTICAL SPENDING AS DETERMINANTS OF HEALTH OUTCOMES IN CANADA

G Emmanuel Guindon () and Paul Contoyannis

Health Economics, 2012, vol. 21, issue 12, 1477-1495

Abstract: Per capita spending on pharmaceutical products has increased substantially in recent decades in Canada. Recent Canadian research by Crémieux et al. concludes that there is a strong statistical relationship between pharmaceutical spending and health outcomes (Health Econ. 2005a; 14: 117, Health Econ. 2005b; 14(2): 107–116). This paper takes a second look at pharmaceutical spending as determinants of health outcomes in Canada. In doing so, it examines the robustness of the findings of Crémieux et al. by considering the appropriateness of the data used and statistical approach utilized. Particular attention is given to the potential for non‐stationarity and spurious regression, issues related to unit heterogeneity and the choice of estimators. In contrast with earlier findings, on the whole, no discernable relationship between spending on private or public pharmaceutical products and infant mortality or life expectancy at 65 is observed. Copyright © 2008 John Wiley & Sons, Ltd.

Date: 2012
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (13)

Downloads: (external link)
https://doi.org/10.1002/hec.1415

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:21:y:2012:i:12:p:1477-1495

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().